Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy

Schomburg, John; Krishna, Suprita; Cotter, Katherine; Soubra, Ayman; Rao, A. Muralikrishna; Konety, Badrinath R.

doi:10.1016/j.urology.2018.01.052

Cited by 18 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, in the historical comparison group, VTE was not discovered in any patients preoperatively, but it developed in 11 patients postoperatively. Six of these patients developed DVT early in the postoperative period; progression to PE was evident in four of these patients, two of whom eventually died . This article suggests that the preoperative discovery of asymptomatic VTE and appropriate management may prevent the postoperative onset of fatal PE.…”

Section: Discussionmentioning

confidence: 86%

“…These frequencies of pre‐treatment VTE are comparable to our results in cervical and endometrial cancers (Table ), suggesting that patients with non‐gynecological cancer may also have considerable frequencies of asymptomatic VTE before treatment. In a study of bladder cancer patients who underwent radical cystectomy, the screened group ( n = 65) and the historical comparison group that did not undergo screening ( n = 78) were compared . In the screened group, asymptomatic DVT was discovered preoperatively in nine patients (13.9%), only three developed DVT, and none progressed to PE postoperatively as a result of preventive treatments such as placement of an inferior vena cava filter.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

Tasaka

Minaguchi

Hosokawa

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: Postoperative pulmonary embolism can be a fatal surgical complication and is thought to occur secondary to asymptomatic venous thromboembolism (VTE) that exists preoperatively in some patients. The purpose of this study was to clarify the frequency and risk factors of pretreatment VTE in gynecological cancer patients. Methods: This study investigated 2086 patients with gynecological cancer (cervix, n = 754; endometrium, n = 862; ovary, n = 470) who underwent initial treatment between 2004 and 2017. Pretreatment VTE screening was performed with D-dimer (DD) levels in these patients. Based on this, the associated risk factors were retrospectively analyzed. Results: Pretreatment VTE was discovered in 7.3% of patients with cervical cancer, 11.5% of those with endometrial cancer and 27.0% of those with ovarian cancer. Significant independent risk factors were: age greater than or equal to 60 years and tumor long diameter greater than or equal to 40 mm for cervical cancer; age greater than or equal to 60 years, stage III/IV advanced disease, clear cell carcinoma and tumor long diameter greater than or equal to 60 mm for endometrial cancer; and age greater than or equal to 60 years, clear cell carcinoma and massive ascites for ovarian cancer. Conclusion: Pretreatment asymptomatic VTE is very frequent in gynecological cancer patients. It may be beneficial to consider measuring DD or performing venous ultrasonography in patients with the above risk factors.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

Tasaka

Minaguchi

Hosokawa

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Before treatment, PE was discovered in 8.8-13.3% of ovarian cancer [13,14], 3.0-4.7% of endometrial cancer [13,15], 1.1-1.4% of cervical cancer [13,16], and 2.9% of advanced pancreatic cancer [17] cases. Moreover, whereas PE was not discovered in bladder cancer or stomach cancer cases, DVT was found in 13.9% and 4.4% of the patients, respectively [18]. VTE is common in ovarian cancer due to vascular dehydration caused by ascites [19] and venous compression by a large tumor [20].…”

Section: Discussionmentioning

confidence: 97%

Malignant Tumor Is the Greatest Risk Factor for Pulmonary Embolism in Hospitalized Patients: A Single-Center Study

Fujieda

Nozue

Watanabe

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundThis study aimed to investigate the background of patients who presented with pulmonary embolism (PE) on contrast-enhanced chest computed tomography (CT) and to explore the risk factors for PE.MethodsThis study included a review of the medical records of all 50,621 patients who were admitted to one community hospital between January 1, 2013 and December 31, 2017. Data on sex, age, risk factors related to blood flow stagnation (obesity, long-term bed rest, cardiopulmonary disease, cast fixation, long-term sitting), risk factors related to vascular endothelial disorder (surgery, trauma/fracture, central venous catheterization, catheter tests/treatments, vasculitis, antiphospholipid antibody syndrome, history of venous thromboembolism (VTE)), and risk factors related to hypercoagulability (malignant tumor, use of oral contraceptives/low-dose estrogen progestin/steroids, infection, inflammatory enteric disease, polycythemia, protein C or protein S deficiency, dehydration) were evaluated.ResultsOf all inpatients, 185 (0.37%) were diagnosed with PE after contrast-enhanced chest CT examination. The rate of discovering PE was significantly greater in women (0.48%, 93/19,409) than men (0.29%, 92/31,212) (P=0.0008). Of the 185 patients with PE, 173 (94%) had some type of risk factor. For both men and women, the most frequent risk factor was a malignant tumor, followed by infection and obesity for men and long-term bed rest and obesity for women. The most common malignant tumor was lung cancer. Of the 12 patients whose clear PE-inducing factor could not be identified, but there is possible involvement of antipsychotic agent.ConclusionsThe risk factors for PE were identified in this single-center, retrospective study.

show abstract

“…17 After pneumonectomy, VTE incidence is high in excised tissue of non-small-cell lung cancer patients. 18 Cancer patients with acutemyocardial infarction or stroke usually are the population of high risk of VTE. 19 DVT occurring in the lower leg is a single sign of metastatic urinary tract cancer, 20 while the cancer patients with central venous catheter placement may develop upper-extremity DVT.…”

Section: Introductionmentioning

confidence: 99%

Dimethyl 2,2′-[2,2′-(ethane-1,1-diyl)bis(1<em>H</em>-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect

Wang¹,

Chen

Zhang

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundDue to the discovery that deep venous thrombosis (DVT) inhibitor is of chemotherapeutic importance, the nano-property of dimethyl 2,2′-[2,2′-(ethane-1,1-diyl) bis(1H-indole-3,2-diyl)]-diacetate (DEBIC), a recently reported antitumor agent, is worthy of characterization.Materials and methodsOne-pot reaction was used to prepare DEBIC. Electrospray Ionization (+/−)-Fourier Transform-Ion Cyclotron Resonance-Mass Spectrometer (ESI(+/−)-FT-ICR-MS), quadrupole Collision Induced Dissociation (qCID) and nuclear overhauser effect spectroscopy spectra were used to present the assembly of DEBIC. Transmission electron microscopy, scanning electron microscopy, atomic force microscopy and Faraday–Tyndall effect were used to visualize the nano-property of DEBIC. Rat models were used to evaluate DVT inhibition and the bleeding reaction of DEBIC.ResultsOne-pot reaction can provide DEBIC in acceptable yield and high purity. In water, rat plasma and lyophilized powders of DEBIC existed as particles of small nano-size. In vivo DEBIC inhibited DVT in a dose-dependent manner. The minimal effective dose of DEBIC was 1.7 μmol/kg. Even the dose of 36 μmol/kg/day DEBIC did not induce bleeding side effect in DVT rats like in warfarin (0.82 μmol/kg/day).ConclusionDEBIC is a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect.

show abstract

Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy

Cited by 18 publications

References 18 publications

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

Malignant Tumor Is the Greatest Risk Factor for Pulmonary Embolism in Hospitalized Patients: A Single-Center Study

Dimethyl 2,2′-[2,2′-(ethane-1,1-diyl)bis(1<em>H</em>-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect

Contact Info

Product

Resources

About

Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy

Cited by 18 publications

References 18 publications

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer

Malignant Tumor Is the Greatest Risk Factor for Pulmonary Embolism in Hospitalized Patients: A Single-Center Study

Dimethyl 2,2&prime;-[2,2&prime;-(ethane-1,1-diyl)bis(1<em>H</em>-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect

Contact Info

Product

Resources

About

Dimethyl 2,2′-[2,2′-(ethane-1,1-diyl)bis(1<em>H</em>-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect